Name | Adenosine Cyclophosphate |
Synonyms | CAMP Acrasin CYCLIC AMP cyclic amp CYCLIC AMP-3',5' 5'-cyclicmonophosphate 5'-Cyclic Monophosphate Adenosine Cyclophosphate Adenosine 3',5'-phosphate Adenosine 3',5'-cyclic monophosphate 3'-5' cyclic adenosine monophosphate adenosine 3',5'-phosphate monohydrate CAMP, ADENOSINE-3',5'-CYCLIC MONOPHOSPHATE 6-(6-Amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide (4aR,6R,7R,7aS)-6-(6-amino-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide |
CAS | 60-92-4 |
EINECS | 200-492-9 |
InChI | InChI=1/C10H12N5O6P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(20-10)1-19-22(17,18)21-7/h2-4,6-7,10,16H,1H2,(H,17,18)(H2,11,12,13)/p-1/t4-,6-,7-,10-/m1/s1 |
Molecular Formula | C10H12N5O6P |
Molar Mass | 329.21 |
Density | 2.47±0.1 g/cm3(Predicted) |
Melting Point | 260°C (dec.)(lit.) |
Boling Point | 56.12°C |
Specific Rotation(α) | -53.7 º (c=0.7,water) |
Flash Point | 378°C |
Water Solubility | 50 mg/mL |
Solubility | Slightly soluble in water, almost insoluble in ethanol or ether. |
Vapor Presure | 1.18E-20mmHg at 25°C |
Appearance | White powder |
Color | white |
Merck | 14,2708 |
BRN | 52645 |
pKa | 1.00±0.60(Predicted) |
Storage Condition | -20°C |
MDL | MFCD00005845 |
Physical and Chemical Properties | Melting point 260°C specific optical rotation -53.7 ° (c = 0.7,water) water solubility 50 mg/mL properties: This product is white or off-white powder, slightly acidic in taste, slightly soluble in water, almost insoluble in ethanol and ether. This product is a protein kinase activator, which can be used for pharmaceutical intermediates and biochemical reagents. The preparation is clinically used for coronary heart disease, myocardial infarction, and can relieve leukemia. |
Use | For the relief of angina and acute, chronic myocardial infarction and other diseases |
Risk Codes | R34 - Causes burns R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
RTECS | AU7357600 |
FLUKA BRAND F CODES | 10-21 |
TSCA | Yes |
HS Code | 29349990 |
Toxicity | oms-hmn:oth 100 mmol/L JIDEAE 65,52,75 |
Reference Show more | 1. Ji Xiaolong, Hou Chunyan, Liu Yanqi. Effects of different sterilization and drying methods on the content of cyclic nucleotides in Jujube [J]. Food Science and Technology 2020 v.45;No.340(02):56-62. 2. Wang Kunhua, Li jiamee, Peng Fei, etc. Effect of radio frequency treatment on drying kinetics and quality characteristics of jujube by medium and short wave infrared spectroscopy [J]. Food Science, 2020(7). 3. Yang Yunfei Yu Ruian Xu Kaicheng et al. Simultaneous determination of cAMP and cGMP in rat plasma by LC-MS/MS [J]. Journal of Pharmaceutical Analysis, 2015, 035(006):1022-1026. 4. Liu Dan, Sui Yuehong, Chen Peng, et al. Study on HPLC fingerprint and quantitative determination of 17 introduced jujube varieties in Tarim Basin [J]. Chinese Herbal Medicine, 2015, 46(021):3248-3252. 5. Li Gao Yan Sun Zhao Qian Guo Qing Mei Zhou Feng Qin. Analysis of nutritional components of four kinds of jujube [J]. Shandong Science 2017 30(03):33-39. 6. Dong Li, raiting Xue. Effect of high temperature and high humidity gas impact treatment on quality of mid-short wave infrared dried jujube [J]. Food Research and Development, 2020,41(22):107-112. 7. Bi, J., chen, Q., zhou, Y. et al. Optimization of Short- and Medium-Wave Infrared Drying and Quality Evaluation of Jujube Powder. Food Bioprocess Technol 7, 2375-2387 (2014). https://doi.org/10.1007/s11947-013-1245-y 8. Gao, Lin, et al. "Original Paper Investigation of Processing Technology for Aged Black Jujube." Food Science and Nutrition 3.4 (2019).ttp://dx.doi.org/10.22158/fsns.v3n4p107 9. Shan, Tong, et al. "Proteomics Based Mongolian Medicine Modified Sugmul-7 Mechanism of Regulating Endocrine Function in Hyperplasia of the Breast." Clinical Medicine Research 9.1 (2020): 11.doi: 10.11648/j.cmr.20200901.13 10. [IF=4.465] Bi Jinfeng et al."Optimization of Short- and Medium-Wave Infrared Drying and Quality Evaluation of Jujube Powder."Food Bioprocess Tech. 2014 Aug;7(8):2375-2387 11. [IF=0] Yongpeng Tong et al."A novel EGFR-TKI inhibitor (cAMP-H3BO3complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes."Oncotarget. 2017 Aug 22; 8(34): 56327-56337 12. [IF=3.645] Fei Li et al."Hydrophilic molecularly imprinted polymers functionalized magnetic carbon nanotubes for selective extraction of cyclic adenosine monophosphate from winter jujube."J Sep Sci. 2021 May;44(10):2131-2142 13. [IF=2.727] Yanlei Zhang et al."Active components and antioxidant activity of thirty-seven varieties of Chinese jujube fruits (Ziziphus jujuba Mill.)."Int J Food Prop. 2021;24(1):1479-1494 |
This product is 6-amino-9-b-d-ribofuranosyl-9h-purin-4, 5 '-cyclic hydrogen phosphate. The content of Cl0H12N506P shall be 97.0% to 103.0% calculated as dry product.
take 0.10g of this product, add 50ml of water to dissolve, and measure according to law (General rule 0631). The pH value should be 2.0~4.0.
take 0.lg of this product, add 50ml of water to dissolve, check according to law (General rule 0901 first method and general rule 0902 first method), the solution should be clear and colorless.
take this product, add water to dissolve and dilute it to a solution containing about 0.5mg per 1ml as a test solution; Take 1ml for precision measurement, put it in a 100ml measuring flask, dilute it with water to the scale, as a control solution. According to the chromatographic conditions under the content determination item, 20 u1 of the test solution and the control solution are accurately measured and injected into the human liquid chromatograph respectively, the chromatogram was recorded to about 4 times the retention time of the main peak (to adenosine triphosphate peak). If there are impurity peaks in the chromatogram of the test solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (1.0%).
take this product, dry to constant weight at 105°C, weight loss shall not exceed 10.0% (General rule 0831).
take l.Og of this product, put it in a cobalt crucible, and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
take 0.50g of this product, inspection according to law (General rule 0821 third law), containing heavy metals shall not exceed 20 parts per million.
take this product, check according to law (General rule 1143), the amount of endotoxin per 1 mg cyclic adenosine monophosphate should be less than 3.7EU.
measured by high performance liquid chromatography (General 0512).
silica gel bonded with octylsilane as filler; Mixed solution of potassium dihydrogen phosphate solution and tetrabutylammonium bromide (6.8g of potassium dihydrogen phosphate and 3.2g of tetrabutylammonium bromide, dissolved in water and diluted to 1000ml, shake, adjust pH to 4.3 with phosphoric acid)-acetonitrile (85:15) as mobile phase; Detection wavelength was 258nm. Take about 10 mg of cyclic adenosine monophosphate reference substance, add 5ml of water to dissolve, add 1ml of 1 mol/ L hydrochloric acid solution, heat in water bath for 30 minutes, cool down, and adjust to Neutral with sodium hydroxide solution, dilute with water to make a solution containing about 0.2mg per 1ml, and inject 20u1 into the human liquid chromatograph to adjust the chromatographic system. The resolution of adenosine cyclophosphate peak and adjacent impurity peaks shall meet the requirements. The number of theoretical plates shall not be less than 2000 and the tailing factor shall be less than 1.4 according to the calculation of the peak of cyclic adenosine monophosphate.
take an appropriate amount of this product, weigh it accurately, add water to dissolve and quantitatively dilute it to make it contain about 0 in each lml. 1 mg solution, as the test solution, the precise amount of 20u1 is injected into the liquid chromatograph, and the chromatogram is recorded. In addition, an appropriate amount of cyclic adenosine monophosphate reference substance is taken and determined by the same method, and the peak area is calculated according to the external standard method.
vasodilators.
sealed and kept in a cool place.
This product is a sterile freeze-dried product of cyclic adenosine monophosphate. Cyclic adenosine monophosphate (C10H12N5O6P) shall be 90.0% to 110.0% of the labeled amount calculated as the average loading.
This product is white or off-white loose block or powder.
take this product, according to the identification test under cyclic adenosine monophosphate, showed the same results.
an appropriate amount of the content (approximately equivalent to 20mg of cyclic adenosine monophosphate) under the item of difference in loading amount is accurately weighed, dissolved by adding water and quantitatively diluted to make a content of approximately cyclic adenosine monophosphate O per 1 ml. A solution of 1 mg was used as a test solution. According to the method under the item of cyclic adenosine monophosphate, obtained.
Same as cyclic adenosine monophosphate.
(l)20mg (2)40mg (3)60mg
sealed and stored in a cool place.
NIST chemical information | information provided by: webbook.nist.gov (external link) |
EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
physiological function | cyclic adenosine monophosphate (cAMP). Adenylate cyclase catalyzes the dehydration condensation of adenosine triphosphate 5 '-phosphate with ribose 3'-hydroxyl, and phosphodiesterase can hydrolyze cAMP to 5 '-AMP and inactivate it. Therefore, the concentration of cAMP depends on the amount of adenylate cyclase and phosphodiesterase activity. Under normal circumstances, the intracellular cAMP content is very small, about 0.1 m; In the hormone, can be increased by more than 100 times. Plasma cAMP concentration was lower than intracellular, about 10 μm. The hormone binds to receptors on the cell surface and activates the G protein located in the cell membrane, which activates the adenylate cyclase located inside the cell membrane and catalyzes the ATP-generating kinase (A kinase), it catalyzes the phosphate modification of a variety of enzyme proteins, and starts the response of target cells, so that a small amount of hormone produces a strong biological effect. Therefore, the hormone is called the first messenger and cAMP is the second messenger. In myocardial tissue, cAMP-activated protein kinase phosphorylates myogenic protein, and Ca2 binds to strengthen muscle contraction; Phosphorylation of membrane protein in sarcoplasmic reticulum, acceleration of Ca2 uptake into sarcoplasmic reticulum, acceleration of muscle fiber relaxation, with the simulation of epinephrine to strengthen myocardial contractility, increase the role of heart rate. In addition, cAMP can inhibit cell division and promote cell differentiation. |
Properties and applications | cyclic adenosine monophosphate is an important substance involved in intracellular metabolism and various biological functions, is the "second messenger" of life information transmission ". In cells, cAMP can directly or indirectly activate a series of protein kinases, promote Ca2 influx, increase phosphorylation, and regulate cell physical and chemical and biological functions. It has the functions of myocardial nutrition, positive muscle strength, vasodilation and anti-arrhythmia. Clinically used for the treatment of myocardial infarction caused by ischemia, angina and heart failure; Not sensitive to digitalis drugs or easy to cause poisoning of congestive heart failure, Pneumonia children with heart failure, can be treated with digitalis, further maintenance of the myocardium. Also as an adjunct to arrhythmia. |
Use | Protein kinase activator. It can improve myocardial hypoxia, dilate coronary artery, enhance myocardial contractility, increase cardiac output and so on. It is used for the adjuvant treatment of angina pectoris and acute myocardial infarction, but its effect is maintained for a short time. Fever, rash occasionally. for the relief of angina and acute and chronic myocardial infarction and other diseases biochemical studies cyclic adenylate-dependent protein kinase (PKA) natural activator; cAMP is an important second messenger and is associated with neurotransmitter or hormone-induced receptor activation in many systems; cAMP/PKA signaling pathway has been shown to inhibit cell proliferation, induce differentiation and induce apoptosis |
production method | with 5 '-AMP as raw material for the preparation of 5'-AMP double salt feed ratio is N, n'-bicyclic hexyl morinidine (m): pyridine (V):5 '-AMP(m): Water (V)= 1:9.62:1.19:1.7. Add N,N'-dicyclohexylmoroxyguanidine and pyridine to the reactor, heat to 80 ° C. Dissolve, add 5 '-AMP and water, dissolve 5'-AMP, vacuum distillation at 80 ° C. To dryness, add a small amount of anhydrous pyridine, vacuum evaporation, repeated two times, the product. 5 '-AMP[N,N'-dicyclohexylmoroxyguanidine, pyridine] →[80 ℃]5'-AMP compound salt preparation of crude cAMP feed ratio is 5 '-AMP compound salt (m): anhydrous pyridine (V): dicyclohexylcarbodiimide (V)= 1:235:1.07. First, mix 1/2 of anhydrous pyridine and bicyclo hexylcarbodiimide, reflux at 140-145 °c, slowly add 5 '-AMP double salt and another 1/2 of anhydrous pyridine mixed solution under reflux, after the addition was completed in about 3H, reflux was continued for 6h, cooling, pyridine was evaporated under reduced pressure at 70 ° C. To dryness, and the residue was dissolved in a mixture of ether and water (1:1.5), the insoluble bicyclohexylurea was removed by filtration, the aqueous layer in the filtrate was separated and washed three times with diethyl ether, and the residual diethyl ether was drained with a water pump. 5 '-AMP double salt [anhydrous pyridine, dicyclohexylcarbodiimide] →[9h] purification of crude cAMP crude cAMP the aqueous layer was adjusted to pH 2 with hydrochloric acid, and the insoluble matter was removed by filtration, the filtrate was adsorbed with 100 mesh of a strong basic styrenic cation exchange resin 001 × 7(732) in an amount of 80-100 times that of 5'-AMP. Then eluted with 1.01mol/L hydrochloric acid, the second absorption peak (E260) was collected, neutralized to Neutral with ammonium bicarbonate, concentrated under reduced pressure at 60 °c until the cAMP content was 15%-20%, filtered, after an equal volume of ethanol (95%) was added to the filtrate, the filtrate was adjusted to pH 2 with 2mol/L hydrochloric acid, filtered, and dried to obtain a cAMP product. Crude cAMP [001 x 7(732) resin, hydrochloric acid, ethanol] →[pH2] finished cAMP. |
category | toxic substances |
flammability hazard characteristics | flammability; Toxic nitrogen oxide and phosphorus oxide fumes generated by heat |
storage and transportation characteristics | warehouse ventilation and low temperature drying |
extinguishing agent | dry powder, foam, sand, carbon dioxide |